SCHEMBL224028

SCHEMBL224028

N#Cc1cccc(NC=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
MAPT P10636 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
KCNA5 P22460 1/20 0.51
IDO1 P14902 1/20 0.49
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
TSHR P16473 1/20 0.47
GRM4 Q14833 1/20 0.46
HSD17B10 Q99714 2/20 0.45
PDK1 Q15118 1/20 0.45
PDK2 Q15119 1/20 0.45
PDK3 Q15120 1/20 0.45
PDK4 Q16654 1/20 0.45
GAA P10253 1/20 0.45
ALOX15 P16050 1/20 0.45
CASP7 P55210 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29960515 1.00 ALDH1A1 (0.53) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL4098064 0.84 ALDH1A1 (0.50) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL18993220 0.82 ALDH1A1 (0.48) ALDH1A1MAPTKMT2AMEN1IDO1
SCHEMBL18599498 0.82 KCNA5 (0.53) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL12129057 0.80 ALDH1A1 (0.67) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL10191908 0.79 ALDH1A1 (0.45) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL953597 0.79 ALDH1A1 (0.56) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL27599896 0.78 KMT2A (0.68) ALDH1A1MAPTKMT2AMEN1IDO1
SCHEMBL224027 0.76 MAPT (0.53) ALDH1A1MAPTKMT2AMEN1KCNA5
SCHEMBL6351856 0.76 MAPT (0.66) ALDH1A1MAPTKMT2AMEN1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO claimed
CN-114890856-B Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative 华南理工大学 2023-08-22 CN disclosed
US-20220413384-A1 PHOTOSENSITIVE COMPOSITION, FILM, OPTICAL FILTER, SOLID-STATE IMAGING ELEMENT, AND IMAGE DISPLAY DEVICE FUJIFILM CORPORATION (JP) 2022-12-29 US disclosed
US-20220143012-A1 Macromolecule-Supported TLR Agonists BOLT BIOTHERAPEUTICS, INC. (US) 2022-05-12 US disclosed
US-9540392-B2 Thienopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-10 US disclosed
US-9540392-B2 Thienopyrimidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-01-10 US disclosed
EP-2852596-B1 THIENOPYRIMIDINES Bayer Pharma AG (DE) 2016-06-22 EP disclosed
EP-2354187-B1 DISPERSED COMPOSITION, POLYMERIZABLE COMPOSITION, LIGHT SHIELDING COLOR FILTER, SOLID-STATE IMAGING ELEMENT, LIQUID CRYSTAL DISPLAY DEVICE, WAFER-LEVEL LENS, AND IMAGING UNIT FUJIFILM CORP (JP) 2016-03-02 EP disclosed
US-9110205-B2 Black curable composition, light-shielding color filter, light-shielding film and method for manufacturing the same, wafer level lens, and solid-state imaging device FUJIFILM CORPORATION (JP) 2015-08-18 US disclosed
US-6316605-B1 FOR USE IN RECORDING MATERIALS FOR THERMAL TRANSFER RECORDING, INK JET RECORDING FUJI PHOTO FILM CO., LTD. (JP) 2001-11-13 US disclosed
US-6228553-B1 SHELF LIFE, STORAGE STABILITY FUJI PHOTO FILM CO., LTD. (JP) 2001-05-08 US disclosed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 WO disclosed
US-5925489-A CONTAINING DIAZONIUM SALT AND PYRROLOPYRIMIDINE COUPLER WHICH REACT WHEN HEATED TO DEVELOP VIOLET TO CYAN COLORS, IMAGE QUALITY AND STABILITY, SHELF LIFE FUJI PHOTO FILM CO., LTD. (JP) 1999-07-20 US disclosed
EP-0710241-A1 NOVEL SILYLATED BENZYLAMINE DERIVATIVES, SALTS THEREOF, METHODS OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PIERRE FABRE MEDICAMENT (FR) 1996-05-08 EP disclosed
WO-1995003313-A1 NOVEL SILYLATED BENZYLAMINE DERIVATIVES, SALTS THEREOF, METHODS OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PIERRE FABRE MEDICAMENT (FR) 1995-02-02 WO disclosed
EP-0000602-B1 PROCESS FOR THE PREPARATION OF ISOCYANATES FROM FORMAMIDES AKZO N.V. (NL) 1981-07-22 EP disclosed
US-4207251-A Catalytic oxidation of formamides to form isocyanates AKZONA INCORPORATED (US) 1980-06-10 US disclosed
EP-0000602-A1 Process for the preparation of isocyanates from formamides AKZO N.V. (NL) 1979-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143012-A1 Macromolecule-Supported TLR Agonists TLR8, TLR7, TLR9 ALDH1A1 2748/4885MAPT 3090/4885KMT2A 972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.